High-Efficiency Lentiviral Transduction of Human CD34

hematopoietic stem cells lentiviral vector transduction efficiency

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
14 Jun 2019
Historique:
received: 11 10 2018
accepted: 16 01 2019
entrez: 22 2 2019
pubmed: 23 2 2019
medline: 23 2 2019
Statut: epublish

Résumé

Hematopoietic stem cell (HSC) gene therapy is curative for various hereditary diseases; however, high-efficiency transduction in HSCs remains crucial to improve the prospects for hemoglobinopathies. We previously optimized lentiviral transduction in human CD34

Identifiants

DOI: 10.1016/j.omtm.2019.01.005 PMID: 30788387 PMC: PMC6370599
pubmed: 30788387
doi: 10.1016/j.omtm.2019.01.005
pii: S2329-0501(19)30008-7
pmc: PMC6370599
doi:

Types de publication

Journal Article

Langues

eng

Pagination

187-196

Références

Science. 2000 Apr 28;288(5466):669-72
pubmed: 10784449
Mol Ther. 2002 Mar;5(3):242-51
pubmed: 11863413
Adv Drug Deliv Rev. 2002 Feb 21;54(2):223-33
pubmed: 11897147
Science. 2002 Jun 28;296(5577):2410-3
pubmed: 12089448
N Engl J Med. 2003 Jan 16;348(3):255-6
pubmed: 12529469
J Virol. 2007 Jan;81(2):639-49
pubmed: 17035328
N Engl J Med. 2009 Jan 29;360(5):447-58
pubmed: 19179314
J Nippon Med Sch. 2009 Jun;76(3):134-47
pubmed: 19602820
J Virol. 2009 Oct;83(19):9854-62
pubmed: 19625395
Nature. 2010 Sep 16;467(7313):318-22
pubmed: 20844535
Mol Ther. 2011 Jan;19(1):133-9
pubmed: 20940706
N Engl J Med. 2010 Nov 11;363(20):1918-27
pubmed: 21067383
Cell Stem Cell. 2011 Apr 8;8(4):445-58
pubmed: 21474107
Gene Ther. 2011 Nov;18(11):1078-86
pubmed: 21544097
Mol Ther. 2012 Oct;20(10):1882-92
pubmed: 22871664
J Gene Med. 2012 Aug;14(8):549-60
pubmed: 22887595
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7306-11
pubmed: 23589850
Mol Ther Nucleic Acids. 2013 Sep 17;2:e122
pubmed: 24045711
Exp Hematol. 2016 Feb;44(2):106-15
pubmed: 26499040
Stem Cells. 2017 Mar;35(3):586-596
pubmed: 27739611
J Virol Methods. 1989 Feb;23(2):187-94
pubmed: 2786000
N Engl J Med. 2017 Mar 2;376(9):848-855
pubmed: 28249145
Mol Ther. 2018 Jan 3;26(1):320-328
pubmed: 29102562
Mol Ther Methods Clin Dev. 2018 Mar 22;9:247-256
pubmed: 29766032
Appl Microbiol. 1971 Dec;22(6):1162-3
pubmed: 4332936

Auteurs

Naoya Uchida (N)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Tina Nassehi (T)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Claire M Drysdale (CM)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Jackson Gamer (J)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Morgan Yapundich (M)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Selami Demirci (S)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Juan J Haro-Mora (JJ)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Alexis Leonard (A)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Matthew M Hsieh (MM)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

John F Tisdale (JF)

Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Classifications MeSH